

HENRY A. WAXMAN, CALIFORNIA  
EDWARD J. MARKEY, MASSACHUSETTS  
RICK BOUCHER, VIRGINIA  
EDOLPHUS TOWNS, NEW YORK  
FRANK PALLONE, Jr., NEW JERSEY  
BART GORDON, TENNESSEE  
BOBBY L. RUSH, ILLINOIS  
ANNA G. ESHOO, CALIFORNIA  
BART STUPAK, MICHIGAN  
ELIOT L. ENGEL, NEW YORK  
ALBERT R. WYNN, MARYLAND  
GENE GREEN, TEXAS  
DIANA DeGETTE, COLORADO  
VICE CHAIRMAN  
LOIS CAPPS, CALIFORNIA  
MIKE DOYLE, PENNSYLVANIA  
JANE HARMAN, CALIFORNIA  
TOM ALLEN, MAINE  
JAN SCHAKOWSKY, ILLINOIS  
HILDA L. SOLIS, CALIFORNIA  
CHARLES A. GONZALEZ, TEXAS  
JAY INSLEE, WASHINGTON  
TAMMY BALDWIN, WISCONSIN  
MIKE ROSS, ARKANSAS  
DARLENE HOOLEY, OREGON  
ANTHONY D. WEINER, NEW YORK  
JIM MATHESON, UTAH  
G.K. BUTTERFIELD, NORTH CAROLINA  
CHARLIE MELANCON, LOUISIANA  
JOHN BARROW, GEORGIA  
BARON P. HILL, INDIANA

ONE HUNDRED TENTH CONGRESS

**U.S. House of Representatives**  
**Committee on Energy and Commerce**  
**Washington, DC 20515-6115**

JOHN D. DINGELL, MICHIGAN  
CHAIRMAN

May 24, 2007

JOE BARTON, TEXAS  
RANKING MEMBER  
RALPH M. HALL, TEXAS  
J. DENNIS HASTERT, ILLINOIS  
FRED UPTON, MICHIGAN  
CLIFF STEARNS, FLORIDA  
NATHAN DEAL, GEORGIA  
ED WHITFIELD, KENTUCKY  
BARBARA CUBIN, WYOMING  
JOHN SHIMKUS, ILLINOIS  
HEATHER WILSON, NEW MEXICO  
JOHN B. SHADEGG, ARIZONA  
CHARLES W. "CHIP" PICKERING, MISSISSIPPI  
VITO FOSSELLA, NEW YORK  
STEVE BUYER, INDIANA  
GEORGE RADANOVICH, CALIFORNIA  
JOSEPH R. PITTS, PENNSYLVANIA  
MARY BONO, CALIFORNIA  
GREG WALDEN, OREGON  
LEE TERRY, NEBRASKA  
MIKE FERGUSON, NEW JERSEY  
MIKE ROGERS, MICHIGAN  
SUE MYRICK, NORTH CAROLINA  
JOHN SULLIVAN, OKLAHOMA  
TIM MURPHY, PENNSYLVANIA  
MICHAEL C. BURGESS, TEXAS  
MARSHA BLACKBURN, TENNESSEE

DENNIS B. FITZGIBBONS, CHIEF OF STAFF  
GREGG A. ROTHSCHILD, CHIEF COUNSEL

The Honorable Michael O. Leavitt  
Secretary  
U.S. Department of Health and Human Services  
200 Independence Avenue, S.W.  
Washington, D.C. 20201

Dear Mr. Secretary:

Since the 110<sup>th</sup> Congress began, Committee staff have requested briefings, documents, and information regarding a range of problems with the operation of the Food and Drug Administration (FDA). Copies of these letters are attached. With the exception of the January 23, 2007, request regarding the generic drug approval process, and the provision of two food safety briefings, all of the other requests from this Committee have been, at best, only partially answered, and several have been ignored altogether. As the attached spreadsheet indicates, these requests for documents and information have been outstanding for one to three months. In sum, none of the document requests has been fulfilled to the satisfaction of the Committee. Moreover, in some instances FDA has produced redacted records to the Committee, without any prior consultation on such redactions.

The delays and the quality of responses to the Committee's requests concerning FDA are unacceptable. With the exception of patient identifiers in medical records, all documents produced to the Committee are to be unredacted. Please understand the seriousness of our position—all questions must be answered and all outstanding documents must be delivered by no later than close of business on Friday, June 1, 2007. After that date, the Committee will consider other options, including compulsory process, to achieve fulfillment of these requests.

The Honorable Michael O. Leavitt  
Page 2

If you have any questions regarding this request, please contact us or have your staff contact John Sopko, Chief Counsel for Oversight with the Committee on Energy and Commerce, at (202) 225-7469.

Sincerely,



John D. Dingell  
Chairman



Bart Stupak  
Chairman  
Subcommittee on Oversight and Investigations

Attachments

cc: The Honorable Joe Barton, Ranking Member  
Committee on Energy and Commerce

The Honorable Ed Whitfield, Ranking Member  
Subcommittee on Oversight and Investigations

The Honorable Andrew C. von Eschenbach, M.D.  
Commissioner, U.S. Food and Drug Administration

**SUBCOMMITTEE ON OVERSIGHT AND INVESTIGATIONS - LETTERS**

<u>Date Sent</u>	<u>Agency</u>	<u>Subject</u>	<u>Response Due</u>	<u>Response Received</u>
Jan. 22, 2007	FDA/Andrew C. von Eschenbach	Contracting Conflicts of Interest	Jan. 25, 2007	Incomplete response, no letter provided
Jan. 29, 2007	FDA/Andrew C. von Eschenbach	Food Safety	Feb. 7, 2007	Incomplete response; Briefing Feb. 23, 2007 (follow up requested); Apr. 18, 2007; Apr. 20, 2007; May 8, 2007
Feb. 6, 2007	FDA/Andrew C. von Eschenbach	Lab Closures	Mar. 1, 2007	Incomplete response; Mar. 2, 2007; Mar. 16, 2007; May 8, 2007
Feb. 15, 2007	FDA/Andrew C. von Eschenbach	Food Safety	Briefing Feb. 23, 2007	Briefing Feb. 23, 2007 (follow up requested)
Feb. 16, 2007	HHS/Michael O. Leavitt	Ketek Records	Feb. 28, 2007	Incomplete response; Mar. 1, 2007; Mar. 29, 2007; Apr. 4, 2007; Apr. 25, 2007
Mar. 8, 2007	HHS/Michael O. Leavitt	Contracting Conflicts of Interest	Mar. 22, 2007	
Mar. 28, 2007	HHS/Michael O. Leavitt	FDA Testimony Mistatement	April 9, 2007	
Mar. 30, 2007	FDA/Andrew C. von Eschenbach	Pet Food	Apr. 13, 2007	
Apr. 12, 2007	FDA/Andrew C. von Eschenbach	Religious Comp Pay	unspecified	
Apr. 12, 2007	FDA/Andrew C. von Eschenbach	FDA Bonuses	unspecified	
Apr. 13, 2007	FDA/Andrew C. von Eschenbach	3/22 OI FDA Hearing Follow up Questions	Apr. 27, 2007	
Apr. 18, 2007	FDA/Andrew C. von Eschenbach	Animal Antibiotics	May 2, 2007	